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ABSTRACT To attempt to locate functionally important
regions of the interferon (IFN) molecule, recombinant human
IFN-a2 was subjected to proteolytic digestion. The bacterial
proteinase thermolysin produced two major complementary
fragments, HuIFN-a2-(1-110) and HuIFN-a2-(111-153). After
reduction with 2-mercaptoethanol and separation of the two
major fragments on NaDodSO4/polyacrylamide gel electro-
phoresis, antiviral activity persisted in the larger, Mr 12,000,
fragment consisting of the amino-terminal 110 amino acids.
The availability of large amounts of recombinant DNA-de-
rived interferon (IFN) has fostered investigation of IFN's
structure-function relationships; however, the specific
structural features required for biologic activity remain
largely unknown. Despite disul'ide bond assignment (1), sec-
ondary structure measurements (2), and investigation of
novel recombinant IFNs, (3, 4), little information is available
as to which areas of the protein may be functionally impor-
tant. Modification of the structure of IFNs by using a variety
of enzymes and chemicals has yielded varied results. Incu-
bation of IFNs with glycosidic enzymes in general does not
appear to alter the antiviral activity (5). Cleavage of IFNs
with endopeptidases such as trypsin or with chemicals such
as cyanogen bromide has thus far been unsuccessful in gen-
erating active fragments (6, 7). In contrast, some active spe-
cies were obtained after treatment with exopeptidases (8),
pepsin (9), and periodate (10); however, reductions in size
were modest with the active species of Mr 15,000 or larger.
To attempt to identify small functional portions of the IFN
molecule we have studied proteolytic fragments of a recom-
binant human IFN, HuIFN-a2, produced by the bacterial
proteinase thermolysin. We report here that proteolysis of
this IFN with thermolysin generates a biologically active
fragment originating from the amino-terminal end of the mol-
ecule.
MATERIALS AND METHODS
Thermolysin was obtained from Calbiochem. HuIFN-a2 (1.5
x 10' units/mg of protein) was the gift of Schering. HuIFN-
aA (2.0 x 108 units/mg of protein) was the gift of Hoffmann-
La Roche. 125I-labeled HuIFN-aA (1251-HuIFN-aA) was
prepared as described (11).
Preparative NaDodSO4/polyacrylamide gel electrophore-
sis (NaDodSO4/PAGE) was performed according to the
method of Laemmli (12). The separating gels were 16% ac-
rylamide/N,N'-methylene bisacrylamide, 0.75 mm in thick-
ness and 12 cm in length. Electrophoresis was performed at
15 mA per slab gel. The gels were stained and destained as
described (13). The stained gel bands were sliced from the
gel and eluted as reported (13). The samples were then as-
sayed for biological activity or dialyzed and lyophilized for
amino acid analysis and amino acid sequence determination
as described (14). Continuous elution of IFN fragments was
done by the method of Hunkapiller (unpublished data).
IFN antiviral assays were performed by using Madin-Dar-
by bovine kidney (MDBK) cells or human foreskin fibro-
blasts with vesicular stomatitis virus as reported (15). Com-
petitive receptor binding assays using 125I-HuIFN-aA and
MDBK cells were performed as described (11).
RESULTS AND DISCUSSION
The effects of thermolysin on the antiviral and receptor bind-
ing activities of IFN are shown in Fig. 1. HuIFN-a2 (0.4
mg/ml) was exposed to thermolysin (0.012 mg/ml) at 370C in
0.1 M Tris HCl buffer with 1 mM CaCl2 at pH 8.0. After 1, 2,
and 4 hr, aliquots were removed for antiviral and competi-
tive binding assays. Half of each sample was reduced with 2-
mercaptoethanol, and both reduced and unreduced portions
were tested for antiviral activity and ability to compete for
binding to the IFN receptor. As indicated by the NaDodSO4/
polyacrylamide gel (Fig. 1 Inset, left portion), digestion over
4 hr resulted in a small reduction of the molecular weight of
unreduced IFN. No remaining native IFN band could be
identified in the 4-hr digest; calculations based on the mini-
mal amount of IFN visible on gels (0.3 pug) and on the
amount of sample applied (8-10 ,sg) indicated that at least
96% of the starting material was cleaved. In spite of this, no
change was seen in either the antiviral activity or binding
activity (Fig. 1). These results are compatible with those of
Wetzel et al., who reported that thermolysin cleaves the car-
boxyl-terminal 13 amino acids without loss of biological ac-
tivity (6).
Reduction of thermolysin-digested IFN with 2-mercap-
toethanol prior to electrophoresis showed (Fig. 1 Inset, right
portion) that this single major enzymatic product contained
two predominant disulfide-linked fragments, which we have
designated "A" and "B." Reduced digest was assayed for
antiviral and receptor binding affinity. After 4 hr of proteoly-
sis, -'30% of the antiviral activity (0.5 log10 unit) and ==80%
of the binding activity of reduced undigested IFN remained.
These activities were not due to residual intact IFN because,
as noted above, digestion was at least 96% complete. Rather,
they reflected biological activity in one or more of the re-
duced IFN fragments. When the antiviral effects of the re-
duced fragments were tested with human foreskin fibroblasts
as the target cell, only 12% of the activity remained after
proteolysis (data not shown). The greater loss in this system
is compatible with prior studies indicating that human fore-
skin fibroblasts may be more sensitive than bovine kidney
cells to modifications of the IFN molecule (18).
To attempt definitive identification of the two fragments,
digestion and NaDodSO4/PAGE were performed on a pre-
parative scale. Each of the two major fragments (Fig. 2) was
Abbreviations: IFN, interferon; MDBK, Madin-Darby bovine kid-
ney.
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FIG. 1. Effect of thermolysin treatment on antiviral and receptor binding activities of IFN. (Inset) Effect of thermolysin on NaDodSO4/poly-
acrylamide gel pattern of unreduced (four left lanes) and reduced (four right lanes) IFN. HuIFN-a2 (0.4 mg/ml) was incubated at 37°C with 0.012
mg of thermolysin per ml in 0.1 M Tris-HCl with 1 mM CaC12, at pH 8 (reaction volume, 100 p.l) (R. Wetzel, personal communication). After 1,
2, and 4 hr, aliquots were removed and divided into two portions, one assayed without further treatment for antiviral and competitive receptor
binding activities and one reduced by treatment with 10% 2-mercaptoethanol at 0C for 1 hr prior to assay. For receptor studies, confluent
monolayers of MDBK cells were exposed to 1251-HuIFN-aA at 0.01 pug/ml for 21/2 hr at 4°C in the presence of unlabeled IFN or proteolytic
fractions. Binding inhibitory activity was computed as: [cpm with 1251-HuIFN-aA alone - cpm with 125I-HuIFN-aA plus digested HuIFN-
a21/[cpm with 125I-HuIFN-aA alone - cpm with 1251-HuIFN-aA plus excess native HuIFN-aA]. For each point, the final concentration of
digested IFN was 0.2 ,ug/ml and the excess unlabeled IFN was 0.65 jug/ml. When inhibitory activity was close to 100%o, studies were repeated
with a dilution (0.02 pug/ml) of the digest to confirm the sensitivity of the binding curve to changes in digest concentration. HuIFN-aA differs
from HuIFN-a2 by one amino acid at position 23 (16, 17).
eluted from the gel, dialyzed, lyophilized, and then subjected
to sequence analysis through the first 20 residues using gas-
phase sequence analysis (14). Each eluted band contained an
apparent single sequence. The larger fragment corresponded
to the amino-terminal portion of the intact molecule. The se-
quence of the smaller fragment began with the leucine at po-
sition 111. Thus, the major proteolytic cleavages are be-
tween residues 110 to 111 and 153 to 154. Molecular weights
for fragments A and B calculated from the amino acid se-
quence of IFN-a2 are 12,490 and 5,420, respectively.
To determine which fragment showed biologic activity,
IFN was digested, reduced with 2-mercaptoethanol, and ap-
plied to a NaDodSO4/polyacrylamide gel system allowing
continuous elution of material from the bottom of the gel
during electrophoresis (unpublished data). Approximately 35
fractions were collected in this way. Aliquots of each frac-
tion were run on gradient analytical gels to determine the
presence and molecular weights of eluted fragments, and an-
other portion of each fraction was assayed for antiviral activ-
ity. Apparent molecular weights estimated from the mobil-
ities in this system were 9,000-10,000 and 6,000 for the two
major fragments. As shown in Fig. 3, activity is identified in
the fractions corresponding to uncleaved IFN and also in
fragment A, the larger of the two major proteolytic frag-
ments corresponding to the amino terminus of the IFN mole-
cule. Based on an average recovery of protein of 50% in this
system (unpublished observations), a minimal specific activ-
ity of 4 x 106 units/mg for the fragment was calculated. A
similar calculation applied to the uncleaved IFN peak recov-
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FIG. 2. Preparative NaDodSO4/PAGE of IFN fragments.
HuIFN-a2 (4.0 mg/ml) was incubated at 37TC with 0.12 mg of ther-
molysin per ml (reaction volume, 100 /.d). Under these conditions,
-90% digestion required only 30 min of incubation. Aliquots were
then reduced with electrophoresis solubilizing buffer containing 3%
2-mercaptoethanol and applied to 16% polyacrylamide gels contain-
ing 0.1% NaDodSO4.
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FIG. 3. Continuous elution of IFN fragments from a NaDodSO4/
polyacrylamide gel. IFN was digested as in Fig. 2 (reaction volume,
86 ,ul); then 20 Ag was applied to the continuous gel elution system.
Fractions of 100 ,ul were collected continuously from the bottom of
the gel during electrophoresis. Positions of IFN and of fragments A
and B were determined by subsequent analytical NaDodSO4/PAGE
of aliquots of each sample.
ered from the gel gave a specific activity of 108 units/mg,
which is comparable to that of the starting material, 1.5 x
108 units/mg. In addition to its antiviral effect, the amino-
terminal fragment also inhibited growth of Daudi cells (result
not shown). In further experiments, we have eluted active
fragments from stained polyacrylamide gels, according to
procedures devised for intact IFN (13). Using this method,
we have detected antiviral activity in fragment A and, in
some experiments, in the smaller fragment as well. It is our
present belief that optimal and stable antiviral activity of the
fragment(s) will depend critically on isolation conditions, in-
cluding appropriate disposition of disulfide bonds (1).
The orientation of IFN on its cell surface receptor has
been investigated in many laboratories using several ap-
proaches, including recombinant DNA techniques, mono-
clonal antibodies against IFN, and the generation of frag-
ments by chemical synthesis or proteolytic cleavage.
HuIFN-as, with deletions of the first 15 amino-terminal ami-
no acid residues and the last 10-13 carboxyl-terminal amino
acid residues, have been shown to exhibit virtually the same
antiviral activity as the parent molecules (3, 6, 19, 20). Stud-
ies with a monoclonal antibody, which recognizes the last 16
carboxyl-terminal amino acid residues of HuIFN-aA, have
confirmed that the carboxyl-terminal region of the HuIFN-
aA molecule is not involved in interaction with the receptor,
for this antibody is capable of binding to HuIFN-aA bound
to its receptor (21, 22). Studies with recombinant DNA-de-
rived HuIFN-aA and HuIFN-aD and their hybrid deriva-
tives have shown that the amino-terminal portion of the
HuIFN-as appears to influence the antiviral activity on hu-
man cells, whereas their carboxyl-terminal portion appears
to influence their activity on mouse cells (3, 23, 24). Of inter-
est, both the parent and hybrid molecules appear to elicit the
antiviral response equally well on bovine kidney cells (3, 23,
24). Therefore, it appears the bovine receptor for HuIFN-a
can accommodate more structural variants than either the
human or mouse HuIFN-a receptors and thus may have the
ability to recognize multiple sequences or conformations of
the HuIFN-as. Our studies are consistent with this proposal,
for HuIFN-a-(1-110) in general exhibits greater antiviral ac-
tivity on bovine cells than human cells.
Availability of an active fragment of IFN will hopefully
facilitate studies on a variety of questions related to the
mechanism of IFN action. For example, although previous
attempts to chemically synthesize active fragments have
been unsuccessful (21, 25), knowledge of a smaller peptide
with activity may help to target areas of the molecule favor-
able for synthesis. Also, the roles of different areas of the
molecule in IFN's various cellular effects may be investigat-
ed.
We thank Dr. N.-Y. Nguyen for amino acid analysis and Dr. R.
Wetzel for helpful discussion.
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